HCPCS Level II code J0225 identifies the injectable agent vutrisiran at a 1 mg dose. Vutrisiran is a specialty RNAi therapeutic used in targeted treatment pathways, and accurate coding for its administration is important for clinical documentation, billing integrity, and payer adjudication across the United States. This code matters nationally because it supports standardized reporting for high-cost, clinically specific biologic therapies and impacts facility and professional billing for outpatient injectable drug delivery.

Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J0225 is used in practice, common sites of service where the injection is administered, and what to expect in payer coverage patterns. The publication summarizes available benchmarks for unit reporting, outlines relevant billing considerations, and provides clinical context for use of vutrisiran as an injectable pharmacologic therapy. Data not available in the input is noted where applicable; the focus remains on code definition, service setting, and payer landscape for a national audience.